Acotec

Executive Summary

Acotec Scientific is a Chinese medical device company specializing in minimally invasive interventional products, particularly drug-coated balloons (DCBs) for cardiovascular and peripheral vascular diseases. Founded in 2011 and headquartered in Beijing, the company has grown to over 500 employees and operates as a publicly traded entity with a commercial-stage portfolio. Acotec's DCBs aim to improve clinical outcomes in angioplasty procedures, addressing a growing market driven by the rising prevalence of cardiovascular diseases in China and globally. The company's competitive edge lies in its proprietary drug-coating technology and established regulatory certifications in China. However, it faces intense competition from both domestic and international players. To sustain growth, Acotec is likely pursuing pipeline expansions, new indication approvals, and international market entry. With a strong domestic foothold and ongoing innovation, the company is positioned for moderate growth, though execution risks and regulatory hurdles remain.

Upcoming Catalysts (preview)

• Q4 2026NMPA approval for next-generation DCB or new indication70% success
• Q2 2027CE mark approval for European market expansion60% success
• H2 2026Top-line results from pivotal clinical trial for peripheral DCB80% success